Save up to 80% on Kisqali from Europe (may be called Kryxana in Europe)
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
European Manufacturing sites:
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Lek Pharmaceuticals d.d.
Verovškova Ulica 57
1526 Ljubljana
Slovenia
Novartis Pharmaceutical Manufacturing LLC
Verovškova Ulica 57
1000 Ljubljana
Slovenia
Information about Kisqali (Ribociclib)
Kisqali is an oral medication that belongs to a class of drugs known as cyclin-dependent kinase (CDK) inhibitors. It is used in combination with other therapies to treat certain types of breast cancer.
Product Highlights
- Used in combination with an aromatase inhibitor or another hormone therapy for postmenopausal women, or in combination with fulvestrant for men and women.
Key Ingredient
Key Benefits
- Effectively slows down the progression of hormone receptor-positive breast cancer.
- Clinical studies have shown an increase in the duration before disease progression when used in combination therapy.
- Provides convenience compared to intravenous therapies.
Direction of Use
- Commonly prescribed at 600 mg daily (three 200 mg tablets) for the first 21 days of a 28-day cycle, followed by a 7-day break.
- Can be taken with or without food; should be taken at the same time each day for consistency.
Safety Concerns
- Monitor for low white blood cell counts (neutropenia), liver function abnormalities, and other blood-related issues.
- May cause heart rhythm changes; monitoring of cardiac function is advised, especially in patients with existing heart conditions.
- Common side effects include fatigue, nausea, vomiting, diarrhea, and rash.
Avoid Kisqali (Ribociclib) If
- Patients with a known allergy to ribociclib or any component of the formulation.
- Those with moderate or severe hepatic impairment should avoid using Kisqali or require dosage adjustments.
- Avoid use with strong CYP3A inhibitors or inducers, which can affect drug metabolism.
- Contraindicated in pregnancy and breastfeeding due to potential harm to the fetus or infant.
